Olanzapine versus Flupenthixol in the Treatment of Inpatients with Schizophrenia: A Randomized Double-Blind Trial

Objective: The atypical antipsychotic olanzapine has extensively been compared with haloperidol, whereas studies vs. other (conventional) neuroleptics are scarce. This exploratory double-blind 4-week study was designed to compare the efficacy and the safety of olanzapine (OLA) and flupenthixol (FLU) which have recently been considered as a ”partially atypical” antipsychotics. Methods: Twenty-eight inpatients with schizophrenia (DSM-IV) were randomly assigned for treatment with OLA (N = 15, 5-20 mg/d) or FLU (N = 13, 5-20 mg/d). The Brief Psychiatric Rating Scale (BPRS) and the Negative Symptoms Rating Scale (NSRS), plus the Patient Global Impression (PGI) and Clinical Global Impression (CGI) scales, were used to assess the efficacy of both compounds; safety was determined by using the Simpson Angus Scale (SAS) and the Abnormal Involuntary Movement Scale (AIMS) and by assessing treatment-emergent adverse events. Non-parametric statistics were applied. Results: BPRS and NSRS scores improved in both groups (exploratory tests; all p ≤ 0.02). Similar results were observed for CGI-Severity, CGI- and PGI-Improvement. There were no significant group differences. Responder rates (at least 40 % decrease in BPRS total) were 9/13 OLA patients (69 %) and 9/12 FLU patients (75 %). EPS events were reported only in the FLU group (p < 0.01); FLU patients needed significantly more anticholinergic medication. Weight gain was higher in OLA patients (p < 0.01). Overall, fewer patients with adverse events were observed in the OLA group (p = 0.04). No significant changes were noted on SAS and AIMS scores. Conclusion: Findings from this study suggest that overall and negative symptomatology improved in both treatment groups, while the safety and tolerability profiles differed for both substances.

References

• 1 Allison D B, Mentore J L, Heo M, Chandler L P, Cappelleri J C, Infante M C. et al . Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatr. 1999;  156 1686-1696
• 2 Baptista T, Kin N MKN, Beaulieu S, De Baptista E A. Obesity and related metabolic abnormalities during antipsychotic drug administration: Mechanisms, management and research perspectives.  Pharmacopsychiatr. 2002;  35 205-219
• 3 Baptista T, Lacruz A, De Mendoza D, Mendoza J M, Silvera R, Angeles F. et al . Body weight gain after administration of antipsychotic drugs.  Pharmacopsychiatr. 2002;  35 36
• 4 Barnes T R, Braude W M. Akathisia variants and tardive dyskinesia.  Arch Gen Psychiatr. 1985;  42 874 -878
• 5 Bauer D, Gaertner H J. Effects of neuroleptics on liver function, the hematopoietic system, blood pressure and temperature regulation. Comparison of clozapine, perazine and haloperidol by evaluating medical records.  Pharmacopsychiatr. 1983;  16 23-29
• 6 Beasley C MJ, Hamilton S H, Crawford A M, Dellva M A, Tollefson G D, Tran P V,. et al . Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.  Eur Neuropsychopharmaco. 1997;  7 125-137
• 7 Buchanan R W. Clozapine: Efficacy and safety.  Schizophr Bul. 1995;  21 579-591
• 8 Casey D E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia.  Psychopharmacolog. 1989;  99(Suppl) S47-53
• 9 Casey D E. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.  Schizophr Re. 1991;  4 109-120
• 10 Casey D E. What makes a neuroleptic atypical?. In: Meltzer HY, editor Novel Antipsychotic Drugs. New York; Raven 1992: 241-251
• 11 Casey D E. Motor and mental aspects of extrapyramidal syndromes.  Int Clin Psychopharmaco. 1995;  10(Suppl 3) 105-114
• 12 Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.  J Clin Psychopharmaco. 1988;  8(4 Suppl) S21-26
• 13 David S R, Taylor C C, Kinon B J, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.  Clin The. 2000;  22 1085-1096
• 14 Fischer-Barnicol D, Lanquillon S, Haen E, Reischle E, Hajak G, Glaser T. et al .Flupentixol - typische und atypische Dosierungen (abstract.) DGPPN Congress. Berlin; Der Nervenarzt 2003 Suppl 2, PS008, 0367: S314
• 15 Glaser T, Philipp M, Lesch O M, Walter H, Patras L, Kurtz G. et al .Flupenthixol and risperidone: equivalent efficacy against negative symptoms in schizophrenia (abstract). CINP Congress 2002 Montréal, Canada;
• 16 Glaser T, Sommermeyer H, Fassbender M, Mauler F. Das Rezeptorbindungsprofil von cis-Flupentixol. In: Glaser T, Soyka M, editors Flupentixol-Typisches oder atypisches Wirkspektrum? Pharmakologie, antipsychotische Wirkung und neue Indikationen. Darmstadt; Steinkopff 1998
• 17 Guy W. ECDEU assessment manual for psychopharmacology. U.S. Department of Health, Education and Welfare publication (ADM) 76 - 338. Rockville; National Institute of Mental Health 1976
• 18 Hoyberg O J, Fensbo C, Remvig J, Lingjaerde O, Sloth-Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.  Acta Psychiatr Scand. 1993;  88 395-402
• 19 Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker W W. Weight gain induced by clozapine.  Eur Neuropsychopharmacol. 1995;  5 437-440
• 20 Iager A C, Kirch D G, Wyatt R J. A Negative Symptom Rating Scale.  Psychiatry Res. 1985;  16 27-36
• 21 Kane J M. The current status of neuroleptic therapy.  J Clin Psychiatry. 1989;  50 322-328
• 22 Kuehn K U, Meyer K, Maier W. Flupentixolein partiell atypisches Neuroleptikum.  Fortschritte der Neurologie-Psychiatrie. 2000;  68(Suppl 1) S38-41
• 23 Leppig M, Bosch B, Naber D, Hippius H. Clozapine in the treatment of 121 out-patients.  Psychopharmacology. 1989;  99(Suppl) S77-79
• 24 Liebzeit K A, Markowitz J S, Caley C F. New onset diabetes and atypical antipsychotics.  Eur Neuropsychopharmacol. 2001;  11 25-32
• 25 Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia.  Int Clin Psychopharmacol. 2001;  16 63-74
• 26 Möller H J, Soyka M. Typische - Atypische Neuroleptika: Versuch einer Begriffsbestimmung. In: Glaser T, Soyka M, editors Flupentixol-Typisches oder atypisches Wirkspektrum? Pharmakologie, antipsychotische Wirkung und neue Indikationen. Darmstadt; Steinkopff 1998
• 27 Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: New case report and review of the literature.  J Am Board Fam Pract. 2001;  14 278-282
• 28 Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients.  Psychopharmacology. 1989;  99(Suppl) S73-76
• 29 Overall J E, Gorham D R. The Brief Psychiatric Rating Scale.  Psychol Res. 1962;  10 799-812
• 30 Owens D G. Extrapyramidal side effects and tolerability of risperidone: a review.  J Clin Psychiatry. 1994;  55(Suppl) 29-35
• 31 Philipp M, Lesch O M, Walter H, Patras L, Kurtz G, Schmauß M . et al . Wirksamkeit von Flupentixol vs. Risperidon auf die Negativsymptomatik schizophrener Patienten.  Psychopharmakotherapie. 2002;  9 67-74
• 32 Simpson G M, Angus J W. A rating scale for extrapyramidal side effects.  Acta Psychiatr Scand. 1970;  212(Suppl) 11-19
• 33 Tollefson G D, Beasley C MJ, Tran P V, Street J S, Krueger J A, Tamura R N . et al . Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.  Am J Psychiatry. 1997;  154 457-465
• 34 Tollefson G D, Birkett M A, Kiesler G M, Wood A J, Lilly Resistant Schizophrenia Study G roup. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.  Biol Psychiatry. 2001;  49 52-63
• 35 Tran P V, Dellva M A, Tollefson G D, Wentley A L, Beasley C M Jr. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.  Br J Psychiatry. 1998;  172 499-505
• 36 Tran P V, Hamilton S H, Kuntz A J, Potvin J H, Andersen S W, Beasley C J. et al . Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.  J Clin Psychopharmacol. 1997;  17 407-418
• 37 Tran P V, Tollefson G D, Sanger T M, Lu Y, Berg P H, Beasley C M Jr. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.  Br J Psychiatry. 1999;  174 15-22
• 38 Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.  Pharmacopsychiatry. 2002;  35 124-126
• 39 Weiden P J, Shaw E, Mann J J. Causes of neuroleptic compliance.  Psychiatric Ann. 1986;  16 571-575
• 40 Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz W F, Sauer H . et al . Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.  Psychopharmacology. 1998;  137 223-232